Research looks at saxagliptin's safety, efficacy in diabetes

09/3/2013 | HealthDay News

Type 2 diabetes patients who took saxagliptin did not have a higher risk of heart attack, stroke or cardiovascular death than those who took a placebo pill, a study in the New England Journal of Medicine indicated. Researchers also found patients in the saxagliptin arm attained better glucose control and reduced insulin therapy requirements. However, researchers noted an increased rate of hospitalization for heart failure among saxagliptin-treated patients, which merits further evaluation.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ